Cohort profile: the PRIMETIME 1 (PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy) cohort – a longitudinal Danish nationwide study of individuals with diabetes and a performed kidney biopsy
The national population registries in Denmark provide a long follow-up period and a distinct opportunity to use superior registry data. This cohort offers a unique opportunity to study the prognostic value of findings in kidney biopsies, the impact of comorbidity and the effect of therapy at the time of kidney biopsy, with a follow-up period increasing over time with running updates.
Authors
- Iain Bressendorff (ORCID: https://orcid.org/0000-0003-2711-4799)
- Frederik Persson (ORCID: https://orcid.org/0000-0001-6242-6638)
- Rikke Borg (ORCID: https://orcid.org/0000-0002-2283-3578)
- K. Jensen (ORCID: https://orcid.org/0000-0002-4424-8708)
- Vanja Kosjerina (ORCID: https://orcid.org/0000-0002-5082-3801)
- Ditte Hansen (ORCID: https://orcid.org/0000-0003-4929-7901)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- Marie Møller
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Frederiksberg Hospital (DK)
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- Zealand University Hospital (DK)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-086086
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- AstraZeneca
- Sanofi
- Gilead Sciences
- Steno Diabetes Center Copenhagen
- Gedeon Richter
- Novo Nordisk
- Vifor Pharma
- Region Sjælland
- Novo Nordisk Fonden